NICE Rejects Roche’s Avastin In Advanced Ovarian Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.'s health care cost regulator says it wouldn't recommend Roche's Avastin as a first-line treatment for advanced ovarian cancer along with standard chemotherapy, on grounds it doesn’t offer value for money.